熱門資訊> 正文

展望Therapeutics启动公开募股;股价下跌

2026-03-24 05:41

Outlook Therapeutics (OTLK) has initiated a best-efforts public offering of common stock and accompanying warrants.
The offering may include pre-funded warrants in place of common stock.
The offering size and terms are not yet finalized.
Proceeds will primarily be used for working capital and general corporate purposes.
OTLK shares down nearly 22% post-market.

More on Outlook Therapeutics

Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset
Seeking Alpha’s Quant Rating on Outlook Therapeutics
Historical earnings data for Outlook Therapeutics
Financial information for Outlook Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。